Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YKYY031 in Advanced Solid Tumors
NCT07631793Phase 1Recruiting
- Sponsor
- Yuekang Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of YKYY031 in solid tumor (2 arms), sponsored by Yuekang Pharmaceutical. Primary endpoints: Dose-Limiting Toxicity at 28 days, Treatment-Emergent Adverse Events and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
YKYY031
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07631793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07631793.